BRCA1 and ovarian cancer: Synthetic lethality between PARP inhibition and BRCA1/BRCA2 mutations is well-known and several PARP inhibitors, including Talazoparib, have been approved by FDA as treatments for patients with deleterious germline BRCA-mutated ovarian cancers [26,43].